Oh Young Bang/LinkedIn
Oct 6, 2025, 03:41
Oh Young Bang: We Are Carefully Preparing to Begin the First Cinical Trial of Exosome Therapy for Stroke in Korea
Oh Young Bang, Professor of Neurology at Samsung Medical Center, CEO at S and E bio, shared on LinkedIn:
”We are carefully preparing to begin the first clinical trial of exosome therapy for stroke in Korea, prioritizing safety over speed.”
Read more on the announcement here.
S and E Bio, a biotechnology company focused on exosomal microRNA-based therapies, has obtained approval from Korea’s Ministry of Food and Drug Safety (MFDS) to begin a Phase 1b clinical trial of its investigational stroke treatment, SNE-101.
This marks the first exosome-based therapy in Korea to advance to clinical trials, representing a significant milestone in the nation’s biopharmaceutical industry.
Stay updated with Hemostasis Today.
-
Dec 15, 2025, 15:58Khaled Musallam Applauds Hatoon Ezzat’s Leadership and Healthcare Advances in Saudi Arabia
-
Dec 15, 2025, 12:46Deborah Ebert Long on Hemophilia Care: Progress, Possibility, and the Power of Listening
-
Dec 15, 2025, 12:34Nathan Connell on Conversion from Eptacog Alfa to Beta
-
Dec 15, 2025, 12:17Danny Hsu on Interdisciplinary Toolkit for Gynecologic Bleeding on Anticoagulation
-
Dec 15, 2025, 12:08Ted Roh: A Historic Milestone for Indonesia’s Health Innovation
-
Dec 15, 2025, 11:28Wolfgang Miesbach Shares Insights from Davide Matino’s Presentation on Marstacimab at ASH25
-
Dec 15, 2025, 11:12Tushar Pandey Awarded for His Enourmous Contribution to Hematology
-
Dec 15, 2025, 11:07DISTRO: Vidya Rajbhoj on AI and Digital Technology to Improve Stroke Rehabilitation
-
Dec 15, 2025, 11:00Ischemic Stroke, AF and Atherosclerotis: Amira Khater on Sufficiency of Anticoagulant Monotherapy